Detailed cookie settings

BEHIND-MS

Coordinator: German Cancer Research Center, Germany

BEHIND-MS aims to understand how Epstein-Barr virus influences multiple sclerosis (MS) development by mapping interactions between the virus, immune system, and brain cells. It will explore if EBV triggers atypical immune responses in MS patients and how EBV and the immune system can cause damage to nerve cells in MS. With better understanding of this interplay, BEHIND-MS will lead to new diagnostic, preventive and therapeutic tools.

CLARITY

Coordinator: UMC Utrecht, The Netherlands

CLARITY aims to identify genetic risk factors and strains of respiratory syncytial virus (RSV) in infants that contribute to severe bronchiolitis. It will also analyze how RSV changes cellular properties that trigger asthma development. AI will be used to generate RSV-induced perturbation signatures and to identify druglike compounds that are able to revert the effects of the RSV-induced perturbations.

ID-DarkMatter-NCD

Coordinator: Medical University Vienna, Austria

Microbes linked to infectious disease have large genomes encoding many antigens possibly associated with immune-related noncommunicable diseases. These hundreds of thousands of structures represent the dark matter of infectious disease immune interactions. ID-DarkMatter-NCD aims to unravel the complex interplay of infectious diseases, genetic, and environmental factors in triggering immune related non-communicable diseases by following a multi-disease and multi-omics approach.

EBV-MS

Coordinator: University of Bergen, Norway

EBV-MS investigates the link between Epstein-Barr virus infection and the development of multiple sclerosis (MS), to determine why some infected individuals develop MS. Two clinical trials will explore whether targeting the virus could prevent or improve the course of MS. Additionally, EBV-MS will develop strategies to detect individuals at high risk of developing MS through machine learning models.

ENT1DEP

Coordinator: Tampere University, Finland

ENT1DEP aims to generate new knowledge about the association between enterovirus infections and type 1 diabetes and the host factors regulating the outcomes of infections. Its ultimate aim is to pinpoint individuals at high risk of developing T1D due to EV infections and intervene early. Researchers are looking into vaccines that could boost immunity to the virus and antiviral drugs that might eliminate persistent infections.

HOMI-LUNG

Coordinator: Nantes Université, France

Homi-lung investigates the relationship between cardiovascular disease progression and the immune and microbiome changes after pneumonia. It aims to enhance our understanding of how pneumonia can lead to more severe cardiovascular and respiratory conditions, thus enabling early identification of at-risk patients, and developing new treatments.

COMMUTE

Coordinator: Fraunhofer Institute SCAI, Germany

COMMUTE aims to estimate the risk of neurodegenerative disorders comorbidities after COVID-19 infection and understand the comorbidity between COVID and neurodegenerative disorders at the mechanistic level. Therefore, they will apply both a hypotheses-free, data-driven approach building on available big data as well as a hypothesis-driven, knowledge-based approach that leveraging the substantial knowledge in the scientific community.

POINT

Coordinator: University of Copenhagen, Denmark

The mission of POINT is to mitigate the long-term health risks associated with COVID-19. It will delve into the relationship between the post-acute phase of COVID-19 and the emergence of non-communicable diseases, with a focus on the pulmonary, cardiovascular, and renal systems. By harnessing advanced biomarkers and a virtual twin model for personalized care, it aims to bridge the gap between scientific discoveries and their practical application in clinical settings.